Implantica Shares Groundbreaking Study Outcomes on RefluxStop™

Implantica Highlights Groundbreaking Study Results

Implantica AG, a leading medtech company known for its innovative technologies in healthcare, recently announced remarkable results from a comprehensive study evaluating their RefluxStop™ device for acid reflux treatment. This study, published in the journal Surgery Open Science, marks a significant milestone in understanding real-world outcomes for gastroesophageal reflux disease (GERD) treatment.

Study Details and Findings

The study is particularly noteworthy as it is the largest of its kind conducted in a real-world setting, involving 79 patients across varying severities of GERD. The research, spearheaded by Priv.-Doz. Dr. Thorsten G. Lehmann, who is the Chief Physician at the Clinic for General and Visceral Surgery Friedrichshafen, provides invaluable insights into the efficacy of the RefluxStop™ device.

Participants were monitored for up to 17 months, with striking results reported. The need for proton pump inhibitors (PPIs) decreased dramatically post-surgery, from 94.9% of participants requiring them before the procedure to just 2.5% afterward. Additionally, patients exhibited a remarkable improvement in their quality of life, as reflected in a 100% median improvement in the GERD health-related quality-of-life (GERD-HRQL) scores.

Benefits for Patients with Complicated Cases

Half of the patients in the study had complex conditions, such as large hiatal hernias or had previously undergone failed anti-reflux surgeries. Typically, these patients experience higher complication rates; however, the findings suggest that RefluxStop™ provides a safer, more effective alternative.

Dr. Peter Forsell, the founder and CEO of Implantica, emphasized the importance of this research. He noted that the ongoing commitment of independent surgeons to collect and share data on RefluxStop™ reinforces its significant potential in transforming GERD treatment. With over 1,000 patients treated throughout Europe in the last five years, the study's favorable outcomes further solidify the device's standing as a pivotal advancement in addressing acid reflux.

Understanding RefluxStop™ Technology

RefluxStop™ represents a paradigm shift in anti-reflux surgery through its innovative approach. Unlike traditional surgical options that encircle the esophagus and may lead to various side effects—such as difficulty swallowing or discomfort—RefluxStop™ does not apply pressure to the esophagus. Instead, it aims to restore the natural position and function of the lower esophageal sphincter.

This unique mechanism not only helps to resolve the immediate issues related to acid reflux but also supports the body's inherent ability to maintain proper digestive functioning. The focus of RefluxStop™ is on reconstructing the essential components of the anti-reflux barrier, which can safeguard against the recurrence of acid reflux symptoms.

Company Overview and Contact Information

Implantica is listed on the Nasdaq First North Premier Growth Market. The company is dedicated to enhancing patient care through advanced technology and has developed a robust pipeline of products designed to innovate treatment methodologies. Alongside their eHealth initiatives, Implantica is committed to effective solutions for managing a wide range of health challenges.

For further information regarding Implantica and their products, please reach out to:

Nicole Pehrsson
Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49

Frequently Asked Questions

What is RefluxStop™?

RefluxStop™ is an innovative medical device designed to treat gastroesophageal reflux disease (GERD) without the complications associated with traditional surgical options.

What were the main findings of the recent study?

The studies showed a dramatic reduction in the need for proton pump inhibitors (PPIs) and significant improvements in quality of life metrics among patients after using RefluxStop™.

How does RefluxStop™ differ from traditional GERD surgeries?

RefluxStop™ does not encircle the esophagus, significantly reducing the likelihood of side effects like swallowing difficulty and discomfort while restoring the sphincter's proper function.

Who conducted the study on RefluxStop™?

The study was conducted by Priv.-Doz. Dr. Thorsten G. Lehmann and involved 79 patients from a top reflux center.

Where can I find more information about Implantica?

Additional information about Implantica and their offerings can be found on their official website.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.